Galmed Pharmaceuticals Ltd.
(NASDAQ : GLMD)

( )
GLMD After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Other
symbolcompany%chnglast%shortavg$volume
HZNPHorizon Therapeutics Plc -2.41%55.856.5%$169.16m
CTLTCatalent, Inc. -0.72%77.452.1%$112.22m
VRXValeant Pharmaceuticals International, Inc. 1.22%17.4014.1%$102.38m
JAZZJazz Pharmaceuticals Plc -0.99%105.552.4%$76.64m
UTHRUnited Therapeutics Corp. -1.27%115.9514.3%$67.46m
BHCBausch Health Cos., Inc. 1.22%17.400.0%$65.42m
ICPTIntercept Pharmaceuticals, Inc. -4.35%43.1316.8%$62.97m
PCRXPacira Biosciences, Inc. -3.84%55.5810.3%$54.77m
AXSMAxsome Therapeutics, Inc. -7.59%76.741.9%$48.18m
ZGNXZogenix, Inc. -2.75%26.497.5%$47.25m
PRGOPerrigo Co. Plc 0.62%55.516.8%$43.49m
MYOKMyoKardia, Inc. -2.41%90.621.8%$43.21m
ARGXargenx SE 0.12%250.820.0%$42.04m
GWPHGW Pharmaceuticals Plc 3.35%132.196.2%$41.23m
ICLRICON plc 1.08%171.794.3%$37.33m

Company Profile

Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company, which engages in the development of oral therapy for the treatment of non-alcoholic steato-hepatitis (NASH). Its product candidate, Aramchol, is a synthetic fatty acid-bile acid conjugate molecule for the oral treatment of NASH in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company was founded by Allen Baharaff and Tuvia Gilat in 2000 and is headquartered in Tel Aviv, Israel.